indazoles has been researched along with Hand-Foot Syndrome in 12 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 12 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chang, YS; Chou, WC; Huang, KG; Huang, PW; Hung, CY; Liau, CT; Liu, CT; Lu, CH; Shen, WC; Su, YL | 1 |
Akaza, H; Chen, C; Kanayama, H; Kim, S; Naito, S; Ozono, S; Shinohara, N; Tarazi, J; Tomita, Y; Tsukamoto, T; Ueda, T; Uemura, H | 1 |
Chiu, YL; LoRusso, P; Ricker, JL; Xiong, H | 1 |
Berlin, J; Cainap, C; Carlson, DM; Fischer, J; Goldberg, RM; Gorbunova, V; Karapetis, CS; Kim, TW; McKee, MD; O'Neil, BH; Qian, J; Qin, Q; Ricker, JL; Van Cutsem, E | 1 |
Cainap, C; Carlson, DM; Chen, PJ; Cheng, Y; Chung, IJ; El-Nowiem, S; Eskens, FA; Gorbunova, V; Huang, WT; Kang, YK; Kudo, M; McKee, MD; Pan, H; Qian, J; Qin, S; Ricker, JL; Toh, HC | 1 |
Iguchi, T; Kato, M; Nakatani, T; Ninomiya, N; Tamada, S; Yamasaki, T | 1 |
Beaumont, JL; Cella, D; Diaz, J; Khan, S; Lai, JS | 1 |
Albiges, L; Choueiri, TK; De Velasco, G; Fay, AP; Heng, DY; Kaymakcalan, MD; Kollmannsberger, CK; Kroeger, N; Lee, JL; McKay, RR; North, SA; Rha, SY; Smoragiewicz, M; Wells, JC; Xie, W | 1 |
Asakura, T; Fujimoto, K; Funatsu, Y; Hirayama, M; Inaki, S; Murata, Y; Oyamada, Y; Satomi, R; Shiraishi, J; Wakaki, M; Yamada, E | 1 |
Balagula, Y; Feldman, DR; Lacouture, ME; Su, X; Wu, S | 1 |
Chen, CS; Chen, WM; Cheng, CL; Chiu, KY; Ho, HC; Li, JR; Ou, YC; Su, CK; Wang, SS; Yang, CK; Yang, CR | 1 |
Fischer, A; Ho, AL; Lacouture, ME; Wu, S | 1 |
2 review(s) available for indazoles and Hand-Foot Syndrome
Article | Year |
---|---|
The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.
Topics: Hand-Foot Syndrome; Humans; Incidence; Indazoles; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Skin; Sulfonamides | 2012 |
The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.
Topics: Axitinib; Hand-Foot Syndrome; Humans; Imidazoles; Incidence; Indazoles; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Risk | 2013 |
6 trial(s) available for indazoles and Hand-Foot Syndrome
Article | Year |
---|---|
Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Axitinib; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Hypertension; Hypothyroidism; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proteinuria; Sorafenib; Treatment Outcome; Young Adult | 2013 |
Results of a phase 1, randomized study evaluating the effects of food and diurnal variation on the pharmacokinetics of linifanib.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Circadian Rhythm; Cross-Over Studies; Drug Administration Schedule; Fatigue; Female; Food-Drug Interactions; Half-Life; Hand-Foot Syndrome; Humans; Hypertension; Indazoles; Male; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Severity of Illness Index | 2014 |
Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Hypothyroidism; Indazoles; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Phenylurea Compounds; Survival Rate; Thrombocytopenia; Young Adult | 2014 |
Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Hypertension; Indazoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Risk Factors; Sorafenib; Treatment Outcome | 2015 |
Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Indazoles; Indoles; Kidney Neoplasms; Lymph Nodes; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Pyrimidines; Pyrroles; Quality of Life; Risk Assessment; Sulfonamides; Sunitinib; Surveys and Questionnaires; Treatment Outcome | 2016 |
Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Axitinib; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hand-Foot Syndrome; Heparin; Humans; Imidazoles; Indazoles; Indoles; Male; Middle Aged; Niacinamide; Ointments; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyrroles; Severity of Illness Index; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
4 other study(ies) available for indazoles and Hand-Foot Syndrome
Article | Year |
---|---|
Hand-foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: A multicenter study in the Asian population.
Topics: Adult; Aged; Asian People; Disease Progression; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Indazoles; Male; Middle Aged; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides; Taiwan; Treatment Outcome | 2018 |
Prolonging survival in metastatic renal cell carcinoma patients treated with targeted anticancer agents: a single-center experience of treatment strategy modifications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Life Style; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Patient Education as Topic; Phenylurea Compounds; Pyrroles; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2015 |
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcin
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Diarrhea; Drug Administration Schedule; Fatigue; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Models, Statistical; Molecular Targeted Therapy; Mucositis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Intimal Sarcoma of the Pulmonary Artery Treated with Pazopanib.
Topics: Aged; Angiogenesis Inhibitors; Hand-Foot Syndrome; Humans; Indazoles; Male; Pulmonary Artery; Pyrimidines; Sulfonamides; Tunica Intima; Vascular Neoplasms | 2016 |